Navigation Links
Cerimon Pharmaceuticals Initiates Phase II Study to Evaluate Simulect(R) (Basiliximab) for Noninfectious Uveitis
Date:7/9/2008

SOUTH SAN FRANCISCO, July 9 /PRNewswire/ -- Cerimon Pharmaceuticals, Inc., announced today it has initiated a Phase II proof-of-concept study of Simulect(R) (basiliximab) for the treatment of noninfectious uveitis, a chronic and potentially sight-threatening inflammation of the eye. The randomized, double-masked, placebo-controlled study will evaluate the safety and efficacy of Simulect as maintenance therapy in 56 patients. During the study, patients will undergo tapering of concomitant immunosuppressive medications, the mainstay of treatments for noninfectious uveitis. This is the second mid-stage trial for basiliximab run by Cerimon, which began a Phase IIb study for patients with moderate-to-severe, steroid-refractory ulcerative colitis (UC) in April 2007.

"The initiation of this proof-of-concept study is part of our overall strategy to seek additional indications for already marketed drugs in areas with significant unmet medical needs," stated Paul Sekhri, President and CEO of Cerimon Pharmaceuticals. "In noninfectious uveitis, we believe Simulect has the potential to significantly improve the quality of life for patients by reducing adverse events often associated with oral or topical corticosteroids while maintaining effective control of their inflammation."

Basiliximab is a monoclonal antibody that selectively blocks the interleukin-2 (IL-2) receptor. This mechanism of action provides highly targeted inhibition of the T-lymphocyte activation that is involved in serious immune-related diseases including noninfectious uveitis. In February 2006, the Company licensed basiliximab from Novartis Pharma AG for the treatment of Inflammatory Bowel Disease (IBD) and initiated a Phase IIb clinical study for the treatment of moderate-to-severe, steroid-refractory ulcerative colitis the following year. In December 2007, Cerimon entered into an agreement with Novartis to conduct a proof-of-concept study for basiliximab for the treatment of noninfectious uveitis.

About Noninfectious Uveitis

Uveitis is an inflammation of the internal structures of the eye. Uveitis can be described by the underlying condition that causes it: autoimmune (noninfectious), bacterial, viral, parasitic and eye trauma, and by the part of the eye that it affects: anterior, intermediate, posterior and panuveitis. Noninfectious uveitis affects approximately two hundred forty thousand people worldwide and can lead to complications, such as glaucoma, cataract and total vision loss. Current treatments include topical and oral corticosteroids, steroidal implants and immunosuppressive drugs; however, these generally have limited success and can lead to adverse events.

About Cerimon Pharmaceuticals

Cerimon Pharmaceuticals, Inc., is a biopharmaceutical company dedicated to developing and commercializing therapeutic products for autoimmune diseases, inflammation and pain. Cerimon believes these new treatment options will enable physicians to further improve the lives of their patients.

Cerimon currently has two drugs in clinical development. The Company's autoimmune program has two development programs. The lead program is a Phase IIb study in which Simulect(R) (basiliximab) is being assessed as a treatment for moderate-to-severe, steroid-refractory ulcerative colitis (UC). The second program is studying Simulect as a treatment for noninfectious uveitis in a Phase II study. Cerimon's lead asset in its pain portfolio is the Company's topical formulations of diclofenac. The Company is in mid-stage clinical testing with its topical diclofenac products.

The Company continues to seek additional assets to add to its development pipeline and is financed by the premier investors MPM, Nomura Phase4 Ventures and OrbiMed Advisors.

For more information on Cerimon, please visit the Company's website at http://www.cerimon.com .


'/>"/>
SOURCE Cerimon Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Cerimon Pharmaceuticals Initiates Phase II/III Clinical Studies to Evaluate its Diclofenac Patch for Mild to Moderate Pain
2. Cerimon Pharmaceuticals Initiates Phase I Clinical Study of Topical Diclofenac Sodium Patch
3. Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis
4. Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV
5. University of Rochester Researcher Named Millennium Pharmaceuticals Career Development Scholar of The Leukemia & Lymphoma Society
6. Peregrine Pharmaceuticals Reports Positive Early Results in Phase II Study of Bavituximab in Breast Cancer
7. Isis Pharmaceuticals Conference Call Notice
8. Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
9. XTL Biopharmaceuticals Announces Completion of Patient Randomization Into the Bicifadine Phase 2b Clinical Trial for the Treatment of Diabetic Neuropathic Pain
10. MAP Pharmaceuticals Reports Positive Pharmacological Response Data for Migraine Product Candidate at the American Headache Society Annual Meeting
11. Phase III Data Show Vanda Pharmaceuticals Tasimelteon (VEC-162) Significantly Improves Sleep in Patients with Chronic Insomnia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... , May 3, 2016 BioNovus Innovations ... Institute for Advancing Medical Innovation (IAMI) today announced ... drugs, diagnostics and medical devices. An ... with rights to license, develop and commercialize medical ... "This partnership represents a significant advance ...
(Date:5/3/2016)... acquired a major investment from Sino-German High-Tech Fund to further expand product development, strengthen its disease modeling capabilities and ... ... ... ... ...
(Date:5/3/2016)... -- ACME Markets, Delaware County ... Delaware County Councilman Dave White announced today ... ACME pharmacies across Delaware County ... (CDC), naloxone has saved 26,463 lives nationwide over the past 20 ... County were authorized to administer naloxone to overdose victims, ...
Breaking Medicine Technology:
(Date:5/6/2016)... Knoxville, Tenn. (PRWEB) , ... May 06, 2016 , ... The joy associated with Mother’s ... for their lives in neonatal intensive care units (NICUs) across the country. For the first ... are joining together to honor these women who spend their Mother’s Day beside a crib ...
(Date:5/6/2016)... , ... May 06, 2016 , ... US Sports Camps ... rugby camp held at Oregon State University this summer. Employing world-class rugby figures, including ... of all skill levels with training on key fundamentals, match play, fitness and more. ...
(Date:5/6/2016)... ... 06, 2016 , ... Bluvault ( Bluvault Inc. ) today ... global clients of Coupa ( Coupa Software ) and other Cloud software, powered ... key component in the suite of innovative implementation services offered by Bluvault. , ...
(Date:5/6/2016)... PA (PRWEB) , ... May 06, 2016 , ... ... does to reduce fat areas around the body, is the most popular ... survey results just released make perfect sense to cosmetic surgeon Dr. Richard Buckley, ...
(Date:5/6/2016)... ... May 06, 2016 , ... Online HR/benefits platforms offer a range ... game for traditional brokers and health plans. “ The Rapid Emergence of Online Benefits ... Atlantic Information Services, Inc. (AIS), will offer an accurate picture of online benefits today, ...
Breaking Medicine News(10 mins):